Average Co-Inventor Count = 9.79
ph-index = 14
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Forma Therapeutics, Inc. (31 from 125 patents)
2. Achillion Pharmaceuticals, Inc. (9 from 104 patents)
3. Valo Health, Inc. (8 from 29 patents)
4. Valo Early Discovery, Inc. (6 from 15 patents)
5. H. Lee Moffitt Cancer Center and Research Institute, Inc. (1 from 290 patents)
54 patents:
1. 12264137 - 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
2. 11919839 - Alpha-cinnamide compounds and compositions as HDAC8 inhibitors
3. 11891365 - 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
4. 11414392 - [6,6] fused bicyclic HDAC8 inhibitors
5. 11345672 - Methods using HDAC11 inhibitors
6. 11279681 - 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
7. 11274084 - 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
8. 11274085 - 3-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
9. 11247987 - Inhibiting ubiquitin specific peptidase 30
10. 10988450 - 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
11. 10988441 - Alpha-cinnamide compounds and compositions as HDAC8 inhibitors
12. 10829462 - 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
13. 10829461 - 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
14. 10829460 - [6,6] fused bicyclic HDAC8 inhibitors
15. 10822316 - 3-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors